Aspo Plc Interim Report November 3, 2025, at 9.00 am EETAspo Plc’s Interim Report, January 1 – September 30, 2025: Steps taken towards Aspo’s strategic vision This is a summary of the Interim Report January 1 – September 30, 2025 of Aspo Plc. The complete report is attached to this release and available at aspo.com. July–September 2025 Net sales, Group total decreased to EUR 144.3 (146.6) millionNet sales from continuing operations decreased to EUR 108.1 (113.7) millionComparable EBITA, Group total grew to ...

Aspocomp Group Plc, Stock Exchange Release, November 3, 2025, at 9:00 a.m. (UCT+2) Release category: Other information disclosed according to the rules of the Exchange Aspocomp’s Board of Directors has approved the company’s strategy for 2026-2030 The revised strategy is focused on strengthening the company’s current market position and growth, especially in the Security, Defense and Aerospace, and Semiconductor segments, due to the increased demand. Aspocomp’s targets are: To achieve more than EUR 100 mil ...

OSB GROUP PLC ISIN: GB00BLDRH36003 November 2025 LEI number: 213800ZBKL9BHSL2K459 OSB GROUP PLC (the “Company”) Transaction in Own Shares and Total Voting Rights The Company announces that on 31 October 2025 it had purchased a total of 183,527 of its ordinary shares of £0.01 each (the "ordinary shares") on the London Stock Exchange, CBOE BXE and CBOE CXE, through the Company's broker Citigroup Global Markets Limited as detailed below. The repurchased ordinary shares will be cancelled. London Stock Exchange ...

TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Sintana Energy Inc. (TSX-V: SEI) ("Sintana" or the "Company") is pleased to provide an update with respect to its previously announced agreement with Challenger Energy Group plc ("Challenger") pursuant to which Sintana will acquire all of the issued and to be issued ordinary share capital of Challenger (the "Acquisition"). It is intended that the Acquisition will be implemented by way of a Court-sanctioned scheme of arrangement under Part IV (section 152) of the Is ...

Sampo plc, stock exchange release, 3 November 2025 at 8:40 am EET Sampo completes its share buyback programme Sampo plc has completed its EUR 200 million share buyback programme, launched on 6 August 2025. The repurchases of shares began on 7 August 2025 and ended on 31 October 2025. During that period, Sampo repurchased 20,484,833 of its own A shares at an average price of EUR 9.76 per share. This corresponds to 0.76 per cent of all Sampo plc’s shares based on the share count prior to the start of this pro ...

产品发布与市场关注度 - 公司在第138届中国进出口商品交易会（广交会）上推出了新的机器人产品系列，其中MAXHUB A3系列智能柔性机械臂为首次公开亮相 [1] - 公司的商用清洁机器人在展会期间获得了全球访客的广泛关注 [4] 国际化商业进展 - 公司的商用清洁机器人已与亚太地区（包括日本、韩国、新加坡）以及欧洲主要市场（包括德国、英国、法国、意大利、荷兰、瑞典、波兰）的客户建立合作伙伴关系 [3] - 该机器人解决方案已在多个海外地点开始初步部署 [3]

股份回购交易详情 - 公司于2025年10月31日通过四个交易场所（AQEU、CEUX、TQEX、XHEL）回购了总计295,568股A股股份 [1] - 本次回购的股份数量分别为：AQEU 7,240股、CEUX 111,363股、TQEX 36,894股、XHEL 140,071股 [1] - 所有回购交易的每日加权平均价格均为每股9.72欧元 [1] 股份回购计划背景 - 公司股份回购计划于2025年8月7日启动，最高回购金额为2亿欧元 [1] - 该计划基于2025年4月23日年度股东大会的授权，并符合欧盟市场滥用法规 [1] 累计持股情况 - 在本次披露的交易完成后，公司总计持有20,484,833股自身A股股份 [2] - 公司持有的自身股份占总股本的比例为0.76% [2]

合作核心内容 - 雷诺集团与吉利控股集团已签署最终协议，将战略合作扩展至巴西市场，涉及零排放和低排放汽车的生产与销售 [1] - 吉利正式收购雷诺巴西公司26.4%的股权，雷诺集团仍为控股股东并继续合并该实体报表 [2] - 此次合作旨在加速双方在巴西这一关键市场的发展，巴西占2025年上半年拉丁美洲汽车注册量的40%以上 [4] 生产与工业安排 - 吉利和雷诺品牌的汽车将在巴西圣若泽杜斯皮尼艾斯的Ayrton Senna工厂共同生产，以提高产量并增强该先进工业综合体的竞争力 [3] - 吉利将获得雷诺巴西公司工业和商业资源的使用权，以加速其在巴西市场的扩张 [2] - 雷诺将利用吉利的GEA新能源架构，为巴西市场扩展其零排放和低排放汽车产品线 [3] 商业与销售策略 - 雷诺巴西公司将在巴西分销吉利汽车的零排放和低排放汽车产品组合，为销售、金融和服务开辟新的增长机会 [4] - 吉利EX5电动SUV已通过雷诺网络运营的专属品牌经销商在巴西市场销售 [2] 合作背景与战略意义 - 此次巴西合作是双方国际战略的决定性一步，建立在工业卓越和技术领导力的基础上 [5] - 合作将使双方在快速变化的汽车市场中更具竞争力、创新性和响应速度 [5] - 双方此前已建立多个全球合作项目，包括共同投资雷诺韩国公司以及成立Horse Powertrain [5][11]

Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva/Gazyvaro, an anti-CD20 monoclonal antibody designed for enhanced B cell depletionGazyva/Gazyvaro has the potential to be a transformative new standard of care for up to 3.4 million people affected by systemic lupus erythematosus (SLE) worldwideIf approved, Gazyva/Gazyvaro would be the first anti-CD20 therapy for SLE to directly target B cells, a key driver of inflammation and disease activity1These positive results follow the r ...

Vivoryon Therapeutics N.V. to Present at Upcoming Conferences Halle (Saale) / Munich, Germany, November 3, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that the Company’s management will participate in the following medical and investor conferences in November: American Society of Nephrology (ASN) Kidney Week 2 ...